Correction to: Safety and Immunogenicity of 1 or 2 Additional Doses of the Adjuvanted Recombinant...
November 2, 2026
Share
Correction to: Safety and Immunogenicity of 1 or 2 Additional Doses of the Adjuvanted Recombinant Zoster Vaccine Administered 5-6 Years After Primary Vaccination in Adults ≥50 Years.
Dupilumab is associated with improved lung functions in patients with COPD and type 2 inflammatio...
November 2, 2026
Share
Dupilumab is associated with improved lung functions in patients with COPD and type 2 inflammation: a post hoc analysis of the BOREAS and NOTUS trials.
Safety and treatment duration of ribociclib + nonsteroidal aromatase inhibitor in HR+/HER2- early...
November 2, 2026
Share
Safety and treatment duration of ribociclib + nonsteroidal aromatase inhibitor in HR+/HER2- early breast cancer: a phase 3 randomized controlled trial (NATALEE).
Treatment Effect of Perioperative (Neoadjuvant and Adjuvant) Apalutamide plus Androgen-deprivatio...
November 1, 2026
Share
Treatment Effect of Perioperative (Neoadjuvant and Adjuvant) Apalutamide plus Androgen-deprivation Therapy Versus Radical Prostatectomy Alone in Patients with High-risk Localized or Locally Advanced Prostate Cancer from the PROTEUS Substudy.
52-Week Safety and Disease Control With Ruxolitinib Cream in Children Aged 2 to 11 Years With Ato...
October 31, 2026
Share
52-Week Safety and Disease Control With Ruxolitinib Cream in Children Aged 2 to 11 Years With Atopic Dermatitis: Results From the Phase 3 TRuE-AD3 Study.
Cardiovascular outcomes and safety of SGLT2 inhibitors in rheumatic diseases: a systematic review...
October 31, 2026
Share
Cardiovascular outcomes and safety of SGLT2 inhibitors in rheumatic diseases: a systematic review of evidence predominantly from systemic lupus erythematosus and systemic sclerosis.